-
公开(公告)号:US20130137636A1
公开(公告)日:2013-05-30
申请号:US13814059
申请日:2011-08-04
申请人: Steffen Goletz , Lars Stockl
发明人: Steffen Goletz , Lars Stockl
IPC分类号: C07K14/59
摘要: The present invention pertains to improved FSH preparations which are capable of stimulating sex steroid release at much lower concentration than the commonly used urinary FSH or recombinant FSH obtained from CHO cells and which act independent of cAMP signaling These improved FSH preparations can be used in infertility treatment.
摘要翻译: 本发明涉及改进的FSH制剂,其能够以比常规使用的尿FSH或从CHO细胞获得的重组FSH更低的浓度刺激性类固醇释放,并且其独立于cAMP信号。这些改进的FSH制剂可用于不孕症治疗 。
-
公开(公告)号:US20120252069A1
公开(公告)日:2012-10-04
申请号:US13511285
申请日:2010-11-24
申请人: Steffen Goletz , Lars Stockl
发明人: Steffen Goletz , Lars Stockl
摘要: The present invention relates to a process for the purification of a glycoprotein comprising subjecting a liquid containing said glycoprotein to the steps of: a) reverse phase chromatography, b) size exclusion chromatography, and c) hydrophobic interaction chromatography. Also provided is a manufacturing process for producing a glycoprotein of interest.
摘要翻译: 本发明涉及一种用于纯化糖蛋白的方法,包括使含有所述糖蛋白的液体经历以下步骤:a)反相色谱法,b)尺寸排阻色谱法,和c)疏水相互作用色谱法。 还提供了用于生产目的糖蛋白的制备方法。
-
公开(公告)号:US08846344B2
公开(公告)日:2014-09-30
申请号:US13511285
申请日:2010-11-24
申请人: Steffen Goletz , Lars Stockl
发明人: Steffen Goletz , Lars Stockl
摘要: The present invention relates to a process for the purification of a glycoprotein comprising subjecting a liquid containing said glycoprotein to the steps of: a) reverse phase chromatography, b) size exclusion chromatography, and c) hydrophobic interaction chromatography. Also provided is a manufacturing process for producing a glycoprotein of interest.
摘要翻译: 本发明涉及一种用于纯化糖蛋白的方法,包括使含有所述糖蛋白的液体经历以下步骤:a)反相色谱法,b)尺寸排阻色谱法,和c)疏水相互作用色谱法。 还提供了用于生产目的糖蛋白的制备方法。
-
公开(公告)号:US09359439B2
公开(公告)日:2016-06-07
申请号:US13816390
申请日:2011-08-10
申请人: Steffen Goletz , Antje Danielczyk , Lars Stoeckl
发明人: Steffen Goletz , Antje Danielczyk , Lars Stoeckl
CPC分类号: C07K16/2863 , A61K2039/505 , C07K16/00 , C07K16/18 , C07K16/3092 , C07K2317/41 , C07K2317/55 , C07K2317/73 , C07K2317/732 , C07K2317/92 , C07K2317/94
摘要: The present invention pertains to a method for controlling the circulation half-life of antibodies by adjusting the amount of sialic acid in the carbohydrates attached to the Fab part of the antibodies. Furthermore, the present invention provides antibodies having an increased circulation half-life.
摘要翻译: 本发明涉及通过调节与抗体Fab部分连接的碳水化合物中的唾液酸的量来控制抗体的循环半衰期的方法。 此外,本发明提供具有增加的循环半衰期的抗体。
-
公开(公告)号:US20120294859A1
公开(公告)日:2012-11-22
申请号:US13574260
申请日:2011-01-20
申请人: Steffen Goletz , Uwe Karsten
发明人: Steffen Goletz , Uwe Karsten
IPC分类号: A61K39/395 , A61P35/02 , C12N5/00 , A61P35/00 , G01N33/53 , G01N33/566
CPC分类号: G01N33/57469 , G01N2333/70596
摘要: The present invention inter alia pertains to therapeutic methods which are based on the use of an agent specifically binding a tumor-associated carbohydrate antigen for the treatment of cancer stem cells and related diseases. Also provided are diagnostic and prognostic methods using a tumor-associated carbohydrate antigen as marker for cancer stem cells.
摘要翻译: 本发明尤其涉及基于特异性结合肿瘤相关碳水化合物抗原用于治疗癌症干细胞和相关疾病的试剂的使用的治疗方法。 还提供了使用肿瘤相关碳水化合物抗原作为癌症干细胞的标志物的诊断和预后方法。
-
公开(公告)号:US20110129570A1
公开(公告)日:2011-06-02
申请号:US12991827
申请日:2009-05-13
申请人: Steffen Goletz
发明人: Steffen Goletz
CPC分类号: A23C9/1203 , A61K39/0011 , A61K2039/523 , A61K2039/542
摘要: The present disclosure relates in one embodiment to a method of producing a fermented food, wherein a raw food material is combined with a starter culture for fermentation, wherein at least one microorganism of the genus Bacteroides and/or at least one microorganism having at least a cell surface structure which corresponds to a human carbohydrate structure is added. Further disclosed are processing aids and fermented foods containing respective microorganisms.
摘要翻译: 在一个实施方案中,本公开涉及一种生产发酵食品的方法,其中将生食材料与用于发酵的起始培养物组合,其中至少一种拟杆菌属和/或至少一种微生物的微生物具有至少一种 加入对应于人碳水化合物结构的细胞表面结构。 进一步公开的是加工助剂和含有微生物的发酵食品。
-
公开(公告)号:US09217038B2
公开(公告)日:2015-12-22
申请号:US13387587
申请日:2010-07-30
申请人: Steffen Goletz , Antje Danielczyk , Renate Stahn , Uwe Karsten
发明人: Steffen Goletz , Antje Danielczyk , Renate Stahn , Uwe Karsten
IPC分类号: A61K39/395 , C07K16/30
CPC分类号: C07K16/3092 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92
摘要: The present invention pertains to anti-mucin antibodies having improved antigen binding and/or recognition properties as well as a method for improving the antigen binding and/or recognition of an anti-mucin antibody. In particular, the present invention is directed to anti-MUC1 antibodies which are useful in the treatment of cancer.
摘要翻译: 本发明涉及具有改善的抗原结合和/或识别性质的抗粘蛋白抗体以及用于改善抗粘蛋白抗体的抗原结合和/或识别的方法。 特别地,本发明涉及可用于治疗癌症的抗MUC1抗体。
-
公开(公告)号:US20130273033A1
公开(公告)日:2013-10-17
申请号:US13814779
申请日:2011-08-10
申请人: Steffen Goletz , Antje Danielczyk
发明人: Steffen Goletz , Antje Danielczyk
IPC分类号: C07K16/28
CPC分类号: C07K16/2863 , C07K2317/24 , C07K2317/565 , C07K2317/567
摘要: The present invention pertains to humanized anti-EGFR antibodies having antigen binding properties similar to those of the murine or chimeric anti-EGFR antibody from which they are derived. In particular, the present invention is directed to humanized anti-EGFR antibodies which are useful in the treatment of cancer.
摘要翻译: 本发明涉及具有与从其衍生的鼠抗体或嵌合抗EGFR抗体相似的抗原结合特性的人源化抗EGFR抗体。 特别地,本发明涉及可用于治疗癌症的人源化抗EGFR抗体。
-
公开(公告)号:US20120128676A1
公开(公告)日:2012-05-24
申请号:US13387587
申请日:2010-07-30
申请人: Steffen Goletz , Antje Danielczyk , Renate Stahn , Uwe Karsten
发明人: Steffen Goletz , Antje Danielczyk , Renate Stahn , Uwe Karsten
IPC分类号: A61K39/395 , C12N1/21 , C12N1/19 , A61P35/04 , G01N33/566 , C07K16/18 , C07H21/04 , A61P35/00 , C12N5/10 , C12N15/63
CPC分类号: C07K16/3092 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92
摘要: The present invention pertains to anti-mucin antibodies having improved antigen binding and/or recognition properties as well as a method for improving the antigen binding and/or recognition of an anti-mucin antibody. In particular, the present invention is directed to anti-MUC1 antibodies which are useful in the treatment of cancer.
摘要翻译: 本发明涉及具有改善的抗原结合和/或识别性质的抗粘蛋白抗体以及用于改善抗粘蛋白抗体的抗原结合和/或识别的方法。 特别地,本发明涉及可用于治疗癌症的抗MUC1抗体。
-
公开(公告)号:US20110319590A1
公开(公告)日:2011-12-29
申请号:US13208253
申请日:2011-08-11
IPC分类号: C07K14/62 , C07K14/435 , C07K14/575 , C07K14/52 , C07K14/54 , C07K14/59 , C07K14/53 , C07K14/55 , C12P21/02 , C07K16/18
CPC分类号: C12N5/0693 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , A61K2039/55566
摘要: The present invention relates to a cell line selected from the group consisting of (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606; (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and subclones of (a) or (b). Additionally, the present invention provides a lysate of the cell lines or a molecule or mixture of molecules obtained from these cell lines as well as dendritic cells loaded with said lysate, co-cultivated or fused with cells from the cell lines, or a molecule or mixture of molecules obtained from these cell lines of the present invention. Moreover compositions, preferably pharmaceutical or vaccine compositions are provided which comprise the cell lines, lysate, molecules, mixture of molecules or dendritic cells of the present invention. In another aspect the present invention relates to methods for producing the aforementioned compositions. Furthermore, methods and uses for vaccination against or treatment or prevention of cancers and/or tumourous diseases are provided.
摘要翻译: 本发明涉及选自(a)具有DSMZ登录号DSM ACC2606的称为NM-F9的细胞系的细胞系; (b)具有DSMZ登录号DSM ACC2605的称为NM-D4的细胞系; 和(a)或(b)的亚克隆。 此外,本发明提供细胞系的裂解物或从这些细胞系获得的分子或分子混合物以及负载有所述裂解物的树突状细胞,与来自细胞系的细胞共培养或融合,或分子或 从本发明的这些细胞系获得的分子的混合物。 此外,提供了包含本发明的细胞系,裂解物,分子,分子或树突状细胞的混合物的组合物,优选药物或疫苗组合物。 另一方面,本发明涉及制备上述组合物的方法。 此外,提供了针对或治疗或预防癌症和/或肿瘤疾病的疫苗接种的方法和用途。
-
-
-
-
-
-
-
-
-